911227-79-7

Basic information

• Product Name: 1’-t-Butoxycarbonyl-5-hydroxy-spiro[chroman-2,4’-piperidin]-4-one
• Synonyms: 1’-t-Butoxycarbonyl-5-hydroxy-spiro[chroman-2,4’-piperidin]-4-one;Tert-Butyl 5-Hydroxy-4-Oxospiro[Chroman-2,4'-Piperidine]-1'-Carboxylate;tert-butyl 5-hydroxy-4-oxospiro[chromane-2,4-piperidine]-1-carboxylate
• CAS NO: 911227-79-7
• Molecular Formula: C18H23NO5
• Molecular Weight: 333.382
• Mol File: 911227-79-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1’-t-Butoxycarbonyl-5-hydroxy-spiro[chroman-2,4’-piperidin]-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1’-t-Butoxycarbonyl-5-hydroxy-spiro[chroman-2,4’-piperidin]-4-one(911227-79-7)
• EPA Substance Registry System: 1’-t-Butoxycarbonyl-5-hydroxy-spiro[chroman-2,4’-piperidin]-4-one(911227-79-7)

Safety Data

• Hazardous Substances Data: 911227-79-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1'-t-Butoxycarbonyl-5-hydroxy-spiro[chroman-2,4'-piperidin]-4-one is used as an opioid agonist for pain treatment. Its molecular structure allows it to interact with opioid receptors in the central nervous system, providing effective analgesic effects. This makes it a valuable compound for the development of pain management therapies, particularly for chronic and severe pain conditions.
As an opioid agonist, 1'-t-Butoxycarbonyl-5-hydroxy-spiro[chroman-2,4'-piperidin]-4-one offers potential benefits in pain treatment, such as a reduced risk of addiction and dependence compared to traditional opioids. However, further research and development are necessary to fully understand its safety, efficacy, and potential side effects in clinical settings.

Upstream product

• 699-83-2 2,6-dihydroxylacetophenone 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Relevant articles and documents

Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: Discovery of N,N-diethyl-4-(5-hydroxyspiro-[chromene-2, 4′-piperidine]-4-yl)benzamide (ADL5859)

Selective δ opioid receptor agonists are promising potential therapeutic agents for the treatment of various types of pain conditions. A spirocyclic derivative was identified as a promising hit through screening. Subsequent lead optimization identified compound 20 (ADL5859) as a potent, selective, and orally bioavailable δ agonist. Compound 20 was selected as a clinical candidate for the treatment of pain.

SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE

Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.